[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"methamphetamine-use-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:methamphetamine-use-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,50,82,108,128,156,176,203,227,252,282,305,339,365,385,412],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100632086","phase-2-semaglutide-for-treatment-of-people-with-methamphetamine-use-disorder-the-shift-study-100632086",false,"NCT07509112","Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study","SHIFT","Inclusion Criteria:\n\n1. Has provided voluntary, written informed consent;\n2. Aged 18 years or older;\n3. Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria);\n4. Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine\u002Fmethamphetamine;\n5. Willing and able to comply with study procedures and follow-up visits;\n6. People of child-bearing potential must agree to use effective contraception during treatment and during the 60 days after treatment end.\n\nExclusion Criteria:\n\n1. Uncontrolled medical or psychiatric conditions that may interfere with participation;\n2. Body mass index less than 22 kg\u002Fm2;\n3. Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c \\>6.5 at screening);\n4. Currently taking a GLP-1 receptor agonist;\n5. Known hypersensitivity or contraindications to GLP-1 receptor agonists as per product information;\n6. Current enrolment in another interventional trial;\n7. Lactating, pregnant or at risk of pregnancy not willing to avoid pregnancy\n8. History of pancreatitis;\n9. History of medullary thyroid cancer;\n10. Current admission to a residential rehabilitation program or inpatient program or planned admission during the study period, which would interfere with participation in study visits or procedures;\n11. Currently experiencing psychosis or current active suicidality\n12. Any condition or circumstance that, in the opinion of the investigator, would compromise the participant's ability to comply with the study procedures, complete protocol requirements, or provide reliable data.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.",[26],"Methamphetamine Use Disorder",[28,29,30,31,32,33,34,35,36],"Substance use disorder","Addiction","Drug use","Methamphetamine","Stimulants","GLP-1","Semaglutide","Ozempic","Wegovy","NOT_YET_RECRUITING","2026-06-23",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":20},"2026-09",{"date":45,"type":20},"2027-03",{"name":47,"class":48},"Kirby Institute","OTHER_GOV",5,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":78,"locationsCount":81},"100551218","cerebellum-prefrontal-paired-pulse-stimulation-for-methamphetamine-use-disorder-100551218","NCT06457230","Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder","Exploring the Mechanisms and Efficacy of Cerebellum-Medial Prefrontal Cortex-Based Paired-Pulse Repetitive Transcranial Magnetic Stimulation for Methamphetamine Use Disorder","Inclusion Criteria\n\nParticipants will be eligible for inclusion if they meet the following criteria:\n\n1. Methamphetamine is the primary substance of use, and the participant meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for moderate or severe methamphetamine use disorder;\n2. aged 18 to 60 years;\n3. normal or corrected-to-normal vision and hearing, and right-handedness;\n4. primary school education or above, with the ability to understand the questionnaires and behavioral task instructions.\n\nExclusion Criteria\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. presence of metal objects in the body, such as metal dentures, orthodontic braces, bone fixation plates, aneurysm clips, or other metallic implants;\n2. severe physical illness or chronic disease, including heart disease, severe hypertension, stroke, epilepsy, or history of head trauma;\n3. comorbid psychiatric disorders, such as bipolar disorder, schizophrenia, or severe depression;\n4. previous participation in transcranial magnetic stimulation- or electroencephalography-related studies;\n5. refusal to participate in the study, poor compliance, or any other contraindications to transcranial magnetic stimulation.",true,"MALE","60 Years",{"count":61,"type":20},90,[63],"NA","To investigate the mechanism and efficacy of a novel repetitive transcranial magnetic stimulation (rTMS) intervention model with paired cerebellar-medial prefrontal cortex (mPFC) pulses on methamphetamine use disorder patients and to develop a novel physiotherapeutic intervention to optimise the treatment and management.",[26],[67,68,31,69,70],"Repetitive transcranial magnetic stimulation","Cerebellum","Cortico-Cortical Paired Associative Stimulation","medial prefrontal cortex","RECRUITING","2026-06-21",{"date":74,"type":41},"2026-06-24",{"date":76,"type":41},"2024-12-24",{"date":43,"type":20},{"name":79,"class":80},"Shanghai Mental Health Center","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":81},"100610362","non-abstinence-outcomes-in-methamphetamine-use-disorder-100610362","NCT07226596","Non-Abstinence Outcomes in Methamphetamine Use Disorder","Advancing Non-Abstinence Outcomes in the Treatment of Methamphetamine Use Disorder","RCT (05)","Inclusion Criteria:\n\n* be age 18 years or older;\n* self-report methamphetamine use in the week prior to screening;\n* provide a methamphetamine-positive urine sample at screening;\n* meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD);\n* be seeking treatment for their methamphetamine use\n* be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up\n* Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.\n\nExclusion Criteria:\n\n* current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians\n* poor venous access precluding blood draws",{"count":91,"type":20},300,[63],"Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.",[26],[96,97,98],"methamphetamine","treatment","behavioral intervention","2026-06-05",{"date":101,"type":41},"2026-06-08",{"date":103,"type":41},"2026-01-14",{"date":105,"type":20},"2031-01-04",{"name":107,"class":80},"William Stoops",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":81},"100592163","early-phase-1-methamphetamine-and-troriluzole-100592163","NCT06989853","Methamphetamine and Troriluzole","Advancing Troiluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study","BED IN 46","Inclusion Criteria:\n\n1. able to speak\u002Fread English,\n2. not seeking treatment for drug use at the time of the study,\n3. female or male between the ages of 18 and 55 years,\n4. recent methamphetamine use verified by methamphetamine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for MUD,\n5. judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for MUD (and OUD for the co-morbid MUD and OUD group, see below) at the time of screening,\n6. ECG, read by a cardiologist, within normal limits,\n7. females using an effective form of birth control and not pregnant or breastfeeding,\n8. no known contraindications (e.g., hepatic disease \\[save for asymptomatic HCV status as cleared by study physician\\]) or allergies to troriluzole. Individuals in the MUD and OUD group must also report recent opioid use, verified by opioid positive urine, as well as fulfillment of DSM-5 diagnostic criteria for OUD with physiologic dependence (determined to not be physically dependent if a participant arrives with a urine sample for drug screening that is negative for a short-acting opioid and does not have a score of 5 or greater on the clinical opioid withdrawal scale \\[COWS\\]).\n\nExclusion Criteria:\n\n1. unable to speak\u002Fread English,\n2. seeking treatment for drug use,\n3. under 18 years or over 55 years,\n4. no recent methamphetamine use as indicated by methamphetamine negative urine and no DSM-5 diagnosis of MUD,\n5. judged to be medically and psychiatrically unhealthy by study physicians at the time of screening,\n6. ECG, read by a cardiologist, outside normal limits,\n7. females not using an effective form of birth control or pregnant or breastfeeding,\n8. blood pressure readings indicative of hypertension (i.e., blood pressure \\> 140\u002F90 mmHg) on 2 consecutive screening visits,\n9. BMI \\\u003C 18 or \\> 30; weight \\\u003C 50 kg,\n10. taking any medications prescribed by a physician for a chronic condition,\n11. any laboratory chemistry values (e.g., LFTs) \\> 3 times normal at screening or during admission,\n12. history of serious physical disease or diagnosis of any disorder (e.g., current hepatic disease \\[save for asymptomatic HCV status; as noted above\\], histories of seizure, diabetes, asthma or CNS tumors) or current or past histories of psychiatric disorder, including current or recent suicidal ideation that would limit compliance in the study, other than MUD or tobacco use disorder (and OUD for the co-morbid MUD\u002FOUD group only) that in the opinion of the study physicians would interfere with participation and\n13. contraindications (e.g., hepatic disease) or allergies to troriluzole.","55 Years",{"count":19,"type":20},[119],"EARLY_PHASE1","This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.",[26],{"date":101,"type":41},{"date":124,"type":41},"2025-08-25",{"date":126,"type":20},"2029-02-28",{"name":107,"class":80},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100609220","methamphetamine-use-disorder-support-in-heart-failure-pilot-study-100609220","NCT07211724","Methamphetamine Use Disorder Support in Heart Failure Pilot Study","Methamphetamine Use Disorder Support in Heart Failure (Meth HF) Pilot Study","Meth-HF","Inclusion Criteria:\n\n* Heart failure diagnosis meeting universal definition criteria with left ventricular ejection fraction ≤ 40%\n* Active methamphetamine use and stated desire to cease (confirmed by patient self-reported history of active use and \u002For positive urine toxicology obtained as part of routine patient care); physician verifying patients meets criteria for MUD.\n* Age 18 years or older\n* Empaneled to LA General Medical Center\u002FDHS\n* Able to provide informed consent (translated consent forms will be used for non-English speakers)\n\nExclusion Criteria:\n\n* Polysubstance use (excluding tobacco and marijuana)\n* Documented history of alcohol use disorder (DSM-5) or alcohol dependence (ICD-11). Intermittent alcohol use below these thresholds (e.g. social use) is not an exclusion.\n* Cardiogenic shock requiring mechanical circulatory support at time of presentation\n* Acute coronary syndrome, acute pulmonary embolism, or hemodynamically significant arrhythmia on admission\n* Pregnancy\n* Acute psychiatric condition requiring immediate treatment or significantly impairing their ability to provide informed consent or participate in study procedures",{"count":137,"type":20},50,[63],"Heart failure (HF) affects over 6 million people in the US and is a major cause of both hospital admissions and death. HF has many causes and contributing factors. One of the most aggressive forms of HF is associated with methamphetamine abuse, which has become its own epidemic in the US over the past twenty years. People who use methamphetamine tend to develop HF at a much younger age, with more severe disease and more serious consequences. A recent analysis using nationwide data, methamphetamine use doubled the risk of death or hospitalizations compared to non-users in patients with HF. Thus, methamphetamine users with HF represent a very high-risk group of patients from a healthcare perspective.\n\nHF may be reversible in some patients who use methamphetamine if patients can achieve 1) abstain from further methamphetamine use and 2) consistently take all the medications that can improve HF. These two goals are very difficult to achieve in practice, as the care of both methamphetamine addiction and HF requires specialized medical expertise and intensive regular follow up of patients. In general, achievement of one goal is not possible without the other. Patients who use methamphetamine have poor adherence to medical follow-up and therapies, and abstinence from methamphetamine is difficult to maintain. This is further complicated because the current model of HF care does not incorporate treatment for methamphetamine use.\n\nThe current study proposes to launch a multidisciplinary clinic that treats both HF and methamphetamine use disorder at the same time. The HF care will be led by a cardiologist while the methamphetamine use treatment will be led by a psychiatric clinical pharmacist trained in addiction medicine. State-of-the-art HF care will include optimization of four pillar HF medications. Methamphetamine use treatment will include counseling and incentivized abstinence known as contingency management (CM). The investigators will manage the patients in the clinic for 6 months total.\n\nThe investigators are interested in demonstrating that this integrated clinic model will result in improved delivery of care for these patients by reporting the rates of successful abstinence from methamphetamine, improved optimization of the four HF medications, and enhanced patient reported quality of life over the 6 months of follow up. The investigators will also collect data on the costs associated with providing this level of care and estimate a range of potential cost-savings.",[141,26],"Heart Failure",[141,143,144,145],"Methamphetamine use disorder","Meth-associated cardiomyopathy","Multidisciplinary","2026-04-28",{"date":148,"type":41},"2026-05-04",{"date":150,"type":20},"2026-05-31",{"date":152,"type":20},"2027-07",{"name":154,"class":80},"University of Southern California",2,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":81},"100556996","implementing-a-contingency-management-program-addressing-methamphetamine-use-for-and-with-the-people-of-hawaii-100556996","NCT06532370","Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii","Inclusion Criteria:\n\n* Admitted trauma patients\n* Age greater than 18 years old\n* Urine drug screen positive for methamphetamines during the current hospitalization\n* Report at least weekly methamphetamine use\n* First methamphetamine use greater than 6 months prior to injury\n* Report at least 4 DSM-V Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)\n* Glasgow Coma Scale ≥13 upon arrival to the emergency department\n* Ability to understand and participate in study procedures\n* Ability to communicate in English\n\nExclusion Criteria:\n\n* Active psychosis (reporting auditory or visual hallucinations)\n* Under ongoing cardiorespiratory monitoring\n* Evidence of moderate or severe traumatic brain injury\n* Patients who are known to be pregnant\n* Prisoner\n* Individuals incarcerated at the time of their hospitalization\n* Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent",{"count":19,"type":20},[63],"The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use.\n\nThe main objectives are to:\n\n* Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury\n* To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.\n\nParticipants will:\n\n* Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit\n* Complete Treatment Effectiveness Assessments at 6 and 12-weeks\n* Engage in a qualitative interview at the end of the CM program",[166,26],"Contingency Managment","2026-03-29",{"date":169,"type":41},"2026-03-31",{"date":171,"type":41},"2024-10-10",{"date":173,"type":20},"2026-12-30",{"name":175,"class":80},"Queen's Medical Center",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":57,"sex":58,"minAge":17,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":81},"100628254","ecg-findings-in-methamphetamine-use-100628254","NCT07459244","ECG Findings in Methamphetamine Use","Electrocardiogram Findings in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Prospective Observational Cohort Study","1. For Methamphetamine Use Disorder (MUD) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MUD according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine Use Disorder (MUD) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MUD\n   * Alcohol use disorder\n2. For Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MP according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n   \\*Exclusion Criteria:\n   * Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder\n3. For Healthy Control Group:\n\n   \\*Inclusion Criteria:\n   * No psychiatric diagnosis\n   * No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Healthy Control Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than schizophrenia\n   * Alcohol\u002Fdrug\u002Fsubstance use","65 Years",{"count":185,"type":20},240,"OBSERVATIONAL","This prospective cohort study aims to examine and compare electrocardiogram (ECG) parameters in subjects diagnosed with Methamphetamine Use Disorder (MUD) and Methamphetamine-Induced Psychotic Disorder (MP) during inpatient psychiatric treatment. ECG findings at hospital admission and during remission prior to discharge will be evaluated and compared between groups. The study also aims to determine whether methamphetamine-induced psychosis is associated with greater ECG abnormalities and increased cardiac risk compared to methamphetamine use without psychosis.",[26,189],"Methamphetamine Induced Psychosis",[31,26,191,192,193],"Methamphetamine-Induced Psychosis","Electrocardiography","Cardiac Risk","2026-03-04",{"date":196,"type":41},"2026-03-09",{"date":198,"type":41},"2025-04-07",{"date":200,"type":20},"2026-05-11",{"name":202,"class":48},"Elazığ Mental Health and Diseases Hospital",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":183,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":81},"100570838","a-pilot-study-of-transcranial-magnetic-stimulation-plus-episodic-future-thinking-for-methamphetamine-use-disorder-100570838","NCT06712446","A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder","Inclusion Criteria:\n\n* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for primary methamphetamine use disorder\n* Be fluent in English and able to understand the consent form\n\nExclusion Criteria:\n\n* Current DSM-5 diagnosis for any illicit substance use disorder other than methamphetamine and marijuana\n* Current DSM-5 diagnosis of moderate or greater severity for alcohol and marijuana use disorder\n* In the opinion of the PI, the presence of any medical, neurological, psychiatric (e.g., psychotic or bipolar disorder), or physical condition, disease, or illness that, may: (a) compromise, interfere, limit, effect or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data\n* Has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments according to the PI:\n\n  1. Structured Clinical Interview for DSM-5 (SCID-5)\n  2. Columbia-Suicide Severity Rating Scale (C-SSRS) Screening - Answers YES to Questions 3, 4, 5, or 6\n  3. Assault \\& homicidal danger assessment tool - Key to danger \\>1\n* Medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps, electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil)\n* History of brain surgery\n* History of an intracranial lesion or any medical or neurological diagnosis\u002Fcondition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension\u002FPseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches \\> 15 days\u002Fmonth, loss of vision or decreased vision\n* Moderate-to-severe heart disease\n* History of stroke\n* Is taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the PI; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:\n\n  1. clozapine\n  2. chlorpromazine\n  3. bupropion\n  4. clomipramine hydrochloride\n  5. amoxapine\n  6. maprotiline hydrochloride\n  7. diphenhydramine\n  8. stimulants other than methamphetamine including the following: Dextroamphetamine and amphetamine, Dextroamphetamine, Lisdexamfetamine dimesylate, Cocaine, Methylphenidate,\n  9. tramadol\n  10. isoniazid\n* Personal history of epilepsy or seizure disorder and\u002For family history including a first-degree relative\n* Serious head injury with loss of consciousness\n* Impending incarceration\n* Pregnant or nursing females\n* Inability to read, write, or speak English\n* For adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope\u002Fpresyncope related to noxious stimuli, anxiety, micturition, or posture)",{"count":210,"type":20},20,[63],"The purpose of this study is to assess impact of repetitive transcranial magnetic stimulation (rTMS)+Episodic Future Thinking (EFT) vs. sham rTMS+EFT on delay discounting and methamphetamine (MA) demand, on vividness of future positive events during EFT training and on frequency of episodic thinking during the week following EFT training",[26],[215,96,216,217],"delay discounting","brain stimulation","episodic future thinking","2026-03-03",{"date":220,"type":41},"2026-03-05",{"date":222,"type":41},"2025-03-26",{"date":224,"type":20},"2026-12-31",{"name":226,"class":80},"The University of Texas Health Science Center, Houston",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":57,"sex":58,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":81},"100627545","lrfn5-and-olfm4-in-methamphetamine-induced-psychosis-100627545","NCT07450027","LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis","Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study","49 Years",{"count":235,"type":20},120,"This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.",[26,238],"Methamphetamine-induced Psychosis",[240,241,31,242,243,244],"LRFN5","OLFM4","Psychotic Disorder","Methamphetamine Psychosis","Psychostimulants","2026-02-27",{"date":194,"type":41},{"date":248,"type":41},"2025-09-01",{"date":250,"type":20},"2026-04-01",{"name":202,"class":48},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":116,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":267,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":81},"100576691","phase-2-feasibility-of-long-term-high-dose-stimulant-for-methamphetamine-use-disorder-100576691","NCT06788587","Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder","Exploring Feasibility and Acceptability of Prolonged Administration of High-Dose Stimulants in People With Methamphetamine Use Disorder: An Extension of a Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Between 18 and 55 years of age at enrollment in the parent ASCME trial;\n2. Diagnosed with a moderate to severe MUD as defined by the DSM-5 criteria;\n3. Enrolled in the parent ASCME trial and completed the study up to and including the end of study visit at Week 20, Day 1;\n4. Interested in avoiding relapse, decreasing methamphetamine use, or abstaining from methamphetamine use;\n5. Presence of ongoing substance use, craving, or significant risk of relapse that according to the study physician, warrants extended treatment for MUD;\n6. If female:\n\n   * Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n   * Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study;\n7. Willing to be randomized to one of 2 study arms and followed for the duration of the trial;\n8. Able to start the study intervention within 28 days after completing the ASCME main trial (study no. CRISM-002);\n9. Able to provide informed consent;\n10. Willing to comply with study procedures;\n11. Able to communicate in English or French\n\nExclusion Criteria:\n\n1. Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; confirmed current hyperthyroidism; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, or unstable medical condition (including electrolyte disturbances) that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent;\n2. Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study;\n3. Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Treatment (OAT) for \\\u003C12 weeks, and not yet at stabilization dose, or at stabilization dose \\\u003C4 weeks;\n4. Current or a history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study;\n5. History of a SAE, hypersensitivity or known allergic reaction to LDX-01 or other amphetamine drugs, or hypersensitivity to the sympathomimetic amines;\n6. Pregnant, nursing, or planning to become pregnant during the study period;\n7. Planned extended absence during the study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study;\n8. Use of an investigational drug for stimulant use disorder during the 30 days before screening, confirmed via self-report or pharmacy records; excluding the use of study medication in the parent ASCME trial;\n9. Use of prescribed amphetamine-type medication or medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion, or mirtazapine) in the 4 weeks before screening;\n10. Current or anticipated need for treatment with any medication that may interact with LDX-01 (e.g., monoamine oxidase inhibitors \\[MAOIs\\]) used currently or within the past 14 days and that would preclude study participant at the discretion of the study physician;\n11. ECG measurement (Bazett method for the correction of QT interval) that indicates a prolonged QTc interval (≥460 milliseconds for females and ≥450 milliseconds for males) at screening;\n12. Any SAEs related to the study product in the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study;\n13. Any compliance issues related to the study product and\u002For study procedures during the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study.",{"count":260,"type":20},80,[23],"Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment.\n\nThe goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group.\n\nParticipants will be placed randomly into one of two groups:\n\n1. TAU and high-dose LDX-01\n2. TAU and placebo",[264,265,29,266,26],"Methamphetamine Abuse","Methamphetamine-dependence","Substance Abuse",[28,268,31,269,270,271,272],"Amphetamines","Lisdexamfetamine","Treatment","Agonist therapy","Feasibility","2026-02-19",{"date":275,"type":41},"2026-02-23",{"date":277,"type":41},"2025-07-18",{"date":279,"type":20},"2027-12",{"name":281,"class":80},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":81},"100587654","why-wait-initiating-contingency-management-in-traumatically-injured-patients-during-hospitalization-100587654","NCT06931197","Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization","Inclusion Criteria:\n\n* Admitted trauma patients\n* Age greater than 18 years old\n* Urine drug screen positive for methamphetamines during the current hospitalization\n* Report at least weekly methamphetamine use\n* First methamphetamine use greater than 6 months prior to injury\n* Report at least 4 Diagnostic and Statistical Manual of Mental Disorders 5th Edition, Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)\n* Glasgow Coma Scale ≥13 upon arrival to the emergency department\n* Ability to understand and participate in study procedures\n* Ability to communicate in English\n* Expected discharge date within 45 days on the day of screening \u002F recruitment\n\nExclusion Criteria:\n\n* Active psychosis (reporting auditory or visual hallucinations)\n* Under ongoing cardiorespiratory monitoring\n* Evidence of moderate or severe traumatic brain injury\n* Patients who are known to be pregnant\n* Prisoners\n* Individuals incarcerated at the time of their hospitalization\n* Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent",{"count":210,"type":20},[63],"This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients.\n\nThe goals are:\n\n* Gather effectiveness data on a CM program for participants in Hawaii who use methamphetamine during hospitalization and following discharge due to trauma injury\n* To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.\n* To assess the rate of leaving against medical advice (AMA) and treatment completion in acute hospital setting in participants.\n* To assess the optimal timing of CM initiation for traumatically injured hospitalized patients by comparing patient outcomes (i.e. duration of CM participation and rates of CM program completion and providing negative urine samples) to NCT06532370 where CM was initiated after discharge from the hospital.\n\nFor total of 12 weeks, participants will:\n\n* Be visited on Mondays\u002FThursdays or Tuesdays\u002FFridays by the research team to complete urine analysis during the hospitalization\n* Visit a follow up clinic up to 2 times per week on Mondays\u002FThursdays or Tuesdays\u002FFridays to complete urinalysis following discharge from the hospital\n* Complete Treatment Effectiveness Assessments at 6 and 12 weeks\n* Engage in qualitative interview at the end of the CM program",[292,26],"Contingency Management",[294,26,295,296],"Contingency management","Contingency management during acute hospitalization","Contingency management in Trauma Injured Patients","2025-12-09",{"date":299,"type":41},"2025-12-17",{"date":301,"type":20},"2026-01-01",{"date":303,"type":20},"2026-07-31",{"name":175,"class":80},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":21,"phases":315,"briefSummary":316,"conditions":317,"keywords":320,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":81},"100609336","champion-combining-hiv-and-meth-prevention-and-treatment-interventions-optimized-for-hiv-negative-msm-100609336","NCT07213258","CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM","CHAMPION","Inclusion Criteria:\n\n1. HIV-negative\n2. Cis-gender male\n3. Age 18-40 years old\n4. Mild or moderate MUD (by DSM-5 SCID criteria)\n5. Anal intercourse with one or more male partners in the past 6 months\n6. Started daily oral PrEP more than 30 days ago and self-reported not always taking PrEP as prescribed in the past 30 days (consistent with PrEP It! inclusion criteria)\n7. Willingness to participate in an mHealth study with a 6-month follow-up\n8. Residing in San Diego or San Francisco County\n\nExclusion Criteria:\n\n1. Residing outside of San Diego or San Francisco County\n2. Any condition that, in the principal investigator's judgment interferes with safe study participation or adherence to study procedures\n3. Not able\u002Fwilling to complete virtual\u002Fremote visits\n4. Not willing to learn to self-collect dried blood spots using a finger stick","40 Years",{"count":314,"type":20},100,[63],"The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are:\n\n* To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates.\n* To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.",[318,26,319],"PrEP Adherence","HIV",[321,322,323,324,325,326,327,328,329],"MSM","HIV Negative","mild MUD","moderate MUD","Methamphetamine Use Disorder (MUD)","CBT4CBT","PrEPAPP","mHealth","Cognitive Behavioral Therapy","2025-10-07",{"date":332,"type":41},"2025-10-08",{"date":334,"type":20},"2025-10-22",{"date":336,"type":20},"2026-08-15",{"name":338,"class":80},"University of California, San Diego",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":346,"maxAge":183,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":363,"locationsCount":81},"100585225","early-phase-1-psilocybin-for-methamphetamine-addiction-100585225","NCT06899594","Psilocybin for Methamphetamine Addiction","A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine","Inclusion Criteria:\n\n* Age 25-65 at time of signing informed consent\n* Identification of methamphetamine as drug of choice\n* Score of at least 3 on the Severity of Dependence Scale\n* Have been at the designated local treatment facility for at least 7 days\n* Use of methamphetamine in the month preceding admission to the treatment center\n* Desire to cease methamphetamine use as indicated by a goal of complete methamphetamine abstinence on the Thoughts about Abstinence questionnaire\n* All English speakers, as all neuropsychological tasks will be given in English\n* No prior psychedelic use or it will have been at least 3 years since their last use of a psychedelic\n* Ability to attend two telehealth and one in person preparatory session appointments to establish comfort, trust and rapport between subjects and the research team and discuss the subjects' goals and aspirations with regard to the psilocybin administration.\n* Ability to attend two integration sessions via telehealth and 3 follow-up assessments in person and via telehealth.\n* Diagnosis of Stimulant Use Disorder - Amphetamine type on the MINI (Mini International Neuropsychiatric Interview), with no other substance dependence diagnoses other than nicotine or cannabis\n* In acute remission from methamphetamine for at least 7 days prior to experimental drug administration as assessed by self-report and confirmed by urine drug screen (UDS) as well as the lack of any acute signs of intoxication on psychoactive drugs other than nicotine\n\nExclusion Criteria:\n\n* Meeting criteria for substance dependence diagnoses other than methamphetamine (except nicotine and cannabis) as assessed by the MINI\n* History of Hallucinogen Use Disorder or Hallucinogen Persisting Perceptive Disorder\n* Women who are pregnant, plan to become pregnant, or are breast feeding\n* Women who do not agree to engage in abstinence or are not using dual contraceptive methods at the time of enrollment and for the study duration\n* Current hypertension (exceeding 140 systolic and 90 diastolic at resting as described below) at screening or during vitals taken pre-dosing\n* Heart rate of less than 60 bpm and greater than 100 bpm at screening or during vitals taken pre-dosing\n* QTc of less than 350 msec or more than 460 msec\n* History of cardiovascular disease (other than controlled hypertension) or cerebral vascular disease\n* Unstable medical or psychiatric conditions or disorders as determined at the discretion of the attending psychiatrist\n* Clear diagnosis of schizophrenia or type 1 bipolar disorder (clear from confusion with drug-induced acute states)\n* Having current or recent (last 6 months) suicidal ideation, assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n* Subjects currently taking medications on the prohibited medications list or that are unwilling\u002Funable to cease medication\n* History of significant brain injury or seizure disorder\n* Inability to understand the informed consent, study purpose and procedures, or other study materials involved in the research study\n* Those with moderate to severe hepatic impairment, as assessed by laboratory parameters.\n* Plans to move away from Shreveport-Bossier area in the next 6 months\n* Subjects whose laboratory blood tests demonstrate clinically significant abnormalities. Clinically acceptable ranges listed below:\n\n  * Complete Blood Count (CBC) Red Blood Cell Count (RBC): 4.5 - 6.0 million cells\u002FµL\n\nHemoglobin (Hb or Hgb):\n\n* For men: 13.8 - 17.2 g\u002FdL\n* For women: 12.1 - 15.1 g\u002FdL\n\nHematocrit (Hct):\n\n* For men: 38.3% - 48.6%\n* For women: 35.5% - 44.9% White Blood Cell Count (WBC): 4,500 - 11,000 cells\u002FµL Platelet Count: 150,000 - 450,000 cells\u002FµL\n\n  * Blood Chemistry with Liver Function Tests Alanine Transaminase (ALT): 7 - 56 units\u002FL Aspartate Transaminase (AST): 8 - 48 units\u002FL Bilirubin (Total): 0.2 - 1.2 mg\u002FdL\n  * Renal Function Tests Blood Urea Nitrogen (BUN): 7 - 20 mg\u002FdL Creatinine: 0.6 - 1.3 mg\u002FdL\n  * If there are abnormalities, or if the results are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to not be clinically significant, or indicative of an unstable medical condition.\n\nProhibited Medications If subjects have a history of taking the following medications, they should be discontinued at least 5 half-lives prior to administering psilocybin.\n\n* Medications that antagonize the serotonin 2A receptor\n* Medications with serotonergic activity (e.g., SSRIs, SNRIs, efavirenz, lithium)\n* Medications that inhibit UGT1A9 or UGT1A10 enzymes\n* Monoamine Oxidase Inhibitors (MAOIs)\n* Medications that inhibit aldehyde or alcohol dehydrogenase","25 Years",{"count":210,"type":20},[119],"The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.",[26],[31,352,353,26,354,355,29,356,357],"Psilocybin","Psychedelics","Stimulant Use Disorder","Methamphetamine Addiction","Substance Use Disorder","Abstinence","2025-10-02",{"date":330,"type":41},{"date":361,"type":41},"2025-04-04",{"date":45,"type":20},{"name":364,"class":80},"Kevin Murnane",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":371,"maxAge":183,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":81},"100540709","testing-an-accelerated-tms-protocol-for-methamphetamine-use-disorder-100540709","NCT06320366","Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder","Inclusion Criteria:\n\n1. Age 21-65 years inclusive;\n2. Meets DSM-5 criteria for past-year moderate or severe methamphetamine use disorder;\n3. By Timeline Follow Back endorses at least 10 days of methamphetamine use out of the last month;\n4. Provides a urine drug screen positive for methamphetamine;\n5. Able to provide informed consent;\n6. No change in current psychiatric medication regimen, or medication free, for at least 4 weeks prior to study entry;\n7. Adequate English proficiency for study consent, and completion of the study instruments.\n\nExclusion Criteria:\n\n1. Lifetime non-substance-induced psychotic disorders, schizophrenia, schizoaffective disorder or bipolar disorder defined by DSM-5;\n2. Current diagnosis of DSM-5 drug use disorder other than stimulant, cannabis or nicotine use disorder;\n3. Non-substance-induced manic episode within the past 3 years or major depressive episode in the past year;\n4. Current clinically significant neurological disorder or medical illness, including history of seizures, cardiovascular disease\u002Fcardiac event, which in the opinion of the study physician would make study participation unsafe;\n5. Presence of a clinically significant abnormality on baseline MRI;\n6. Inability to have an MRI;\n7. Currently breastfeeding, is currently pregnant or lack of use of effective contraception in women of childbearing age, as assessed by urine pregnancy test and self-report (participants will consent to continue effective contraceptives during the study);\n8. Active criminal justice involvement (i.e., any unresolved legal problems that could jeopardize continuation or completion of the study);\n9. History of head injury with loss of consciousness for more than 15 minutes;\n10. Diagnosis of dementia;\n11. Prescribed benzodiazepines or anticonvulsants;\n12. Currently enrolled in formal substance use disorder treatment;\n13. Metal implants or non-removable metal objects above the waist;\n14. Lifetime history of prior clinical treatment with TMS;\n15. Serious risk of suicide or homicide;\n16. Unable\u002Funwilling to follow the study procedures;\n17. History of intractable migraine;\n18. Assessed to be at risk for alcohol or opioid withdrawal.","21 Years",{"count":210,"type":20},[63],"The investigators will evaluate the effects of an accelerated Transcranial Magnetic Stimulation (TMS) protocol of the left dorsolateral prefrontal cortex (DLPFC) for moderate to severe methamphetamine use disorder. This is a randomized parallel group design to assess feasibility and safety, evaluate efficacy (use, craving) and identify magnetic resonance imaging (resting state and cue craving) associated with group\u002Foutcomes.",[26],"2025-09-29",{"date":378,"type":41},"2025-10-03",{"date":380,"type":41},"2024-09-03",{"date":382,"type":20},"2028-05-31",{"name":384,"class":80},"University of Colorado, Denver",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":16,"minAge":346,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":21,"phases":395,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":81},"100560536","deep-tms-of-neural-circuits-associated-with-stimulant-use-disorder-100560536","NCT06578429","Deep TMS of Neural Circuits Associated With Stimulant Use Disorder","Deep TMS Neuromodulation of Neural Circuits Associated With Stimulant Use Disorder","Inclusion:\n\n* Must be within the age range of 25-75.\n* Participants must meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for moderate to severe MUD (≥4 diagnostic symptoms).\n* Participants must be able to obtain a Motor Threshold (MT), which will be determined during the screening process.\n* Participants must have an adequately stable condition and environment to enable attendance at scheduled clinic visits.\n* Participants must be able to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participation in study procedures in English.\n* If participants are on a medication regimen for comorbid symptoms, that regimen will be stable for the duration of the study and patient will be willing to remain on this regimen during the treatment phase.\n* Participants must be fluent in English\n\nExclusion criteria:\n\n* Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, ferromagnetic metal in the head and body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device\u002Fobject in the head and body within 30 cm of the treatment coil.\n* General medical condition, disease, or neurological disorder that interferes with the assessments or participation.\n* Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.\n* Current substance abuse as determined by positive toxicology screen\n* Have a mass lesion, cerebral infarct, or other active CNS disease, including a seizure disorder.\n* A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.\n* Severe impediment to vision, hearing and\u002For hand movement, as this is likely to interfere with the ability to follow study protocols.\n* Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).\n* Taking benzodiazepines or neuroleptic medications, or any medication known to alter seizure threshold.\n* Acute or unstable chronic illness.\n* Current or lifetime history of bipolar disorder or psychosis.\n* Participation in another concurrent intervention-based clinical trial.","75 Years",{"count":394,"type":20},30,[63],"This study aims to evaluate the efficacy of deep transcranial magnetic stimulation (dTMS) as a treatment for Veterans with a methamphetamine use disorder (MUD).",[26,398],"Transcranial Magnetic Stimulation",[400,401,402,403],"Veterans","Deep Transcranial Magnetic Stimulation (dTMS)","Neuroimaging","Relapse","2025-09-10",{"date":406,"type":41},"2025-09-12",{"date":408,"type":41},"2025-03-15",{"date":224,"type":20},{"name":411,"class":80},"Stanford University",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":58,"minAge":17,"maxAge":59,"enrollmentInfo":419,"targetDuration":4,"studyType":186,"phases":4,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":81},"100599555","methamphetamine-cue-reactivity-100599555","NCT07086014","Methamphetamine Cue-reactivity","Cue Reactivity Modulation in MSM With Methamphetamine Use Disorder","Inclusion Criteria:\n\n* Ability to understand and give informed consent\n* Identify as either MSM or non-MSM\n* Males; Age 18-60\n* DSM-5 Diagnosis of MUD (Methamphetamine Use Disorder)\n* Have appropriate abstinence duration \\[i.e., current Methamphetamine users (MA): 2 weeks (range: 1-3 weeks); MA-abstinent: 3 months (range: 2-4 months)\\]\n* Treatment-seeking MUD must be in a treatment facility for substance use disorder, with MA as the primary drug (at the first visit)\n* Treatment-seeking MUD must be abstinent from MA use for approximately 2 weeks (range: 1-3 weeks) at enrollment.\n\nExclusion Criteria:\n\n• Women",{"count":420,"type":20},88,"In this observational cohort study, the researchers propose to first identify a psychophysiological marker of methamphetamine cue-reactivity and its incubation with abstinence from methamphetamine use (MUD) and examine group-differences between men who have sex with men (MSM) and non-MSM MUD.\n\nThe primary objective is to identify psychophysiological markers of methamphetamine (MA) cue-reactivity and its abstinence incubation. The secondary objective is to examine group-differences in methamphetamine use disorder (MUD) individuals between homosexual men (MSM) and heterosexual men (non-MSM). The primary endpoint is to assess incubation of cue-reactivity longitudinally with its reduction in cognitive reappraisal, and the secondary endpoint is to examine the impact of cognitive reappraisal on clinical outcomes of methamphetamine use disorder (MUD) in homosexual men (MSM).\n\n2-year long study. Screening and enrollment will be done at different locations of the Addiction Institute of Mount Sinai. The EEG session will be done at Icahn School of Medicine at Mount Sinai. Participation in the research study will be for a single EEG session.",[26],[96,424,425,426,427,428],"cue-reactivity","craving","EEG","incubation","cognitive reappraisal",{"date":430,"type":41},"2025-07-25",{"date":432,"type":41},"2024-08-19",{"date":434,"type":20},"2025-08-30",{"name":436,"class":80},"Icahn School of Medicine at Mount Sinai"]